During the pathogenesis of MetSy, there is a reduced endothelial NOS activity and NO bioavailability, consequently leading to endothelial dysfunction, with compensatory activation of iNOS, compensating the lack of NO, which is in line with our results [46]. The gene discussed is NOS3; the disease is endothelial dysfunction.